A review of Peyronie's disease insurance coverage.

Peyronie’s cross sectional analysis erectile dysfunction insurance

Journal

Sexual medicine
ISSN: 2050-1161
Titre abrégé: Sex Med
Pays: England
ID NLM: 101631053

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 28 06 2024
revised: 17 09 2024
accepted: 29 09 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Peyronie's disease (PD) is a fibroproliferative disorder that causes an abnormal curve of the penis resulting in pain, discomfort, and erectile dysfunction with management options including correctional surgery, penile external/internal devices, shock wave therapy (SWT), intralesional Verapamil (IV), and collagenase To investigate the insurance coverage of these treatment options. The authors performed a cross-sectional analysis of the top US insurance policies for coverage of PD. Companies were chosen based on their market share and enrollment. Their policies were identified through a Web-based search and telephone interviews, and the companies' medical necessity criteria were defined. The online policies were then re-examined for interval change 3 years later. There are significant discrepancies for in coverage for the different modalities of Peyronie's treatment. Of the 100 companies examined, only 54% of companies had a policy that directly addressed the treatment coverage for PD. The most covered treatment was CCH injections with 37 companies providing unanimous coverage ( Insurance coverage of PD should be aligned with current medical literature to better increase access to care. This study is limited by the updated policies of insurance companies and future applicability. Additionally, this study assumes that a written policy will provide coverage and may overestimate the actual extent of coverage. Finally, this study only addressed some of the common treatment options of PD and did not expand on all possible treatment options. Differing rates for modalities of treatment may present a barrier for patients to receive individualized and adequate treatment for PD.

Sections du résumé

Background UNASSIGNED
Peyronie's disease (PD) is a fibroproliferative disorder that causes an abnormal curve of the penis resulting in pain, discomfort, and erectile dysfunction with management options including correctional surgery, penile external/internal devices, shock wave therapy (SWT), intralesional Verapamil (IV), and collagenase
Aim UNASSIGNED
To investigate the insurance coverage of these treatment options.
Methods UNASSIGNED
The authors performed a cross-sectional analysis of the top US insurance policies for coverage of PD. Companies were chosen based on their market share and enrollment. Their policies were identified through a Web-based search and telephone interviews, and the companies' medical necessity criteria were defined. The online policies were then re-examined for interval change 3 years later.
Outcomes UNASSIGNED
There are significant discrepancies for in coverage for the different modalities of Peyronie's treatment.
Results UNASSIGNED
Of the 100 companies examined, only 54% of companies had a policy that directly addressed the treatment coverage for PD. The most covered treatment was CCH injections with 37 companies providing unanimous coverage (
Clinical Implications UNASSIGNED
Insurance coverage of PD should be aligned with current medical literature to better increase access to care.
Strengths & Limitations UNASSIGNED
This study is limited by the updated policies of insurance companies and future applicability. Additionally, this study assumes that a written policy will provide coverage and may overestimate the actual extent of coverage. Finally, this study only addressed some of the common treatment options of PD and did not expand on all possible treatment options.
Conclusion UNASSIGNED
Differing rates for modalities of treatment may present a barrier for patients to receive individualized and adequate treatment for PD.

Identifiants

pubmed: 39450208
doi: 10.1093/sexmed/qfae071
pii: qfae071
pmc: PMC11500605
doi:

Types de publication

Journal Article

Langues

eng

Pagination

qfae071

Informations de copyright

Published by Oxford University Press on behalf of The International Society for Sexual Medicine 2024.

Déclaration de conflit d'intérêts

The authors have no conflict of interests to disclose.

Auteurs

Nicholas Hricz (N)

Division of Plastic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.

Kevin Schlidt (K)

Department of Surgery, Sinai Hospital of Baltimore, Baltimore, MD 21215, United States.

Michael Ha (M)

Division of Plastic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.

Seray Er (S)

Division of Plastic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.

Katarina Stark (K)

Department of Urology, Virginia Mason Medical Center, Seattle, WA 98101, United States.

Esther Jung (E)

Department of Surgery, Sinai Hospital of Baltimore, Baltimore, MD 21215, United States.

Fan Liang (F)

Department of Plastic & Reconstructive Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, United States.

Yvonne M Rasko (YM)

Division of Plastic Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.

Classifications MeSH